Home
News
Create
Screeners
Insights
Samrat Pharmachem
205.
75
-2.90
(-1.39%)
Market Cap
₹63.60 Cr
PE Ratio
-38.50
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-1.39%
1M
-8.74%
6M
-35.29%
1Y
-37.71%
5Y
+41.55%
View Company Insights
Latest news about Samrat Pharmachem
Samrat Pharmachem Reports Q3 FY26 Loss of Rs 45.95 Lakhs Against Prior Year Profit
3 hrs ago
Today
Samrat Pharmachem Limited reported a net loss of Rs 45.95 lakhs for Q3 FY26 compared to a profit of Rs 278.48 lakhs in Q3 FY25, marking a significant deterioration in financial performance. For the nine-month period, the company posted a loss of Rs 127.57 lakhs against a profit of Rs 751.14 lakhs in the previous year. Despite the challenging profitability metrics, total income from operations remained relatively stable at Rs 6,382.71 lakhs for the quarter. The results were approved by the Board of Directors on February 13, 2026, and published in compliance with regulatory requirements.
Samrat Pharmachem Reports Q2 FY26 Loss Despite Revenue Growth
Nov 15, 2025
Samrat Pharmachem Reappoints Key Executives, Maintaining Family Leadership
Jul 25, 2025
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation